BUY Conviction4/5 Analysis quality80/100 Price target32 now
Hogue suggests Meridian Bioscience (VIVO) as a buy, highlighting its rare integrated life sciences and diagnostics capabilities, strong projected revenue growth of 31% this year, and increasing operating profitability. The stock is considered cheap at 2.6 times sales for its growth rate, has a strong balance sheet with more cash than debt, and analysts have a price target 56% higher than the current price.
“The average analyst price target of 32 a share puts this stock 56 percent higher than the current price”